In the first human clinical trial conducted in the United States, single and multiple dosing
of FB2001 in multiple dose groups was partially completed，and FB2001 demonstrated good safety
and tolerability. The bridge study of FB2001 will be conducted in China to evaluated the
safety and PK of FB2001 in healthy Chinese population. This is a randomized, double-blind,
placebo-controlled study of single and multiple dosing, with multiple dosing once daily for 5
days.